Updated on 3 July 2014
This is the seventh edition of the BioSpectrum Asia Pacific Bioscience Industry Survey
This is the seventh edition of the BioSpectrum Asia Pacific Bioscience Industry Survey and the 2014 Survey provides a broad overview, performance, and trends of the bioscience industry in this region. Executed over a period of two months, the survey is limited to publicly listed companies in the bioscience industry in the Asia Pacific region.
BioSpectrum's definition of bioscience includes pharma, biotech, and medtech companies in the region. We followed a twin approach of sending the questionnaire and talking to experts, besides using the financial data of the publicly listed companies from annual reports and information published with the stock exchanges.
The biggest challenge in the entire exercise has been arriving at the figures for the calendar year as several companies have different financial reporting systems.
Further, the data captured is in local currencies and it had to be converted to US dollar equivalent. We sieved through the annual reports of over 400 companies and finally closed our survey for 320 companies that qualified for the $1 million revenue cut-off. We collected the annual reports, quarterly results, half-yearly results, and then arrived at the revenue figures.
The survey covered all the bioscience companies that are listed in the stock exchanges in Asia Pacific, excluding Japan. For all the companies, the revenue for the 12-month period (January to December) for 2013 have been considered for the purpose of ranking and analysis. The exclusions to the calendar year are marked (*).